To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy
Cell Systems · 2024
DOI: 10.1016/j.cels.2024.04.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Systems, 2024. Verfasst von Maximilian A R Strobl und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Mathematical Oncology, Moffitt Cancer Center, Tampa, FL, USA; Department of Translational Hematology & Oncology Research, Cl…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Ovarian Neoplasms. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, AstraZeneca, NCI.
Abstract (Originalsprache)
Toxicity and emerging drug resistance pose important challenges in poly-adenosine ribose polymerase inhibitor (PARPi) maintenance therapy of ovarian cancer. We propose that adaptive therapy, which dynamically reduces treatment based on the tumor dynamics, might alleviate both issues. Utilizing in vitro time-lapse microscopy and stepwise model selection, we calibrate and validate a differential equation mathematical model, which we leverage to test different plausible adaptive treatment schedules. Our model indicates that adjusting the dosage, rather than skipping treatments, is more effective at reducing drug use while maintaining efficacy due to a delay in cell kill and a diminishing dose-response relationship. In vivo pilot experiments confirm this conclusion. Although our focus is toxicity mitigation, reducing drug use may also delay resistance. This study enhances our understanding of PARPi treatment scheduling and illustrates the first steps in developing adaptive therapies for new treatment settings. A record of this paper's transparent peer review process is included in the supplemental information.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrated Mathematical Oncology, Moffitt Cancer Center, Tampa, FL, USA; Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, OH, USA. Electronic address: stroblm@ccf.or…
- Department of Obstetrics and Gynecology, University of Tennessee Health Science Center, Memphis, TN, USA; Division of Gynecologic Oncology, West Cancer Center and Research Institute, Memphis, TN, USA.
- Department of Integrated Mathematical Oncology, Moffitt Cancer Center, Tampa, FL, USA.
- Department of Integrated Mathematical Oncology, Moffitt Cancer Center, Tampa, FL, USA; Cancer Biology and Evolution Program, Moffitt Cancer Center, Tampa, FL, USA.
- Gynecologic Oncology Program, Moffitt Cancer Center, Tampa, FL, USA.
- Wolfson Centre for Mathematical Biology, University of Oxford, Oxford, UK. Electronic address: maini@maths.ox.ac.uk.
Förderung
- NCI NIH HHS
- AstraZeneca
- NCI
Zitieren
APA
Strobl, M. A. R., Martin, A. L., West, J., Gallaher, J., Robertson-Tessi, M., Gatenby, R., Wenham, R., Maini, P. K., Damaghi, M., & Anderson, A. R. A. (2024). To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy. Cell Systems. https://doi.org/10.1016/j.cels.2024.04.003
Vancouver
Strobl MAR, Martin AL, West J, Gallaher J, Robertson-Tessi M, Gatenby R, et al. To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy. Cell Systems. 2024. doi:10.1016/j.cels.2024.04.003
BibTeX
@article{Strobl2024,
author = {Strobl, Maximilian A R and Martin, Alexandra L and West, Jeffrey and Gallaher, Jill and Robertson-Tessi, Mark and Gatenby, Robert and Wenham, Robert and Maini, Philip K and Damaghi, Mehdi and Anderson, Alexander R A},
title = {To modulate or to skip: De-escalating PARP inhibitor maintenance therapy in ovarian cancer using adaptive therapy},
journal = {Cell Systems},
year = {2024},
doi = {10.1016/j.cels.2024.04.003}
}
EUVIMED